Huntington’s disease

This week in drug discovery (21 – 25 August)

26 August 2022

News round-up for 21-25 August by DDW Editor Reece Armstrong A treatment for Monkeypox, spider venom for drug discovery and funding for international start-ups are some of the stories in this week’s news round-up. Covid researchers launch Monkeypox study   A new study investigating a potential treatment for people who have been diagnosed with monkeypox has […]

Bayer to advance Huntington’s Disease gene therapy trial  

23 August 2022

A Phase I/II clinical trial targeting a treatment for Huntington’s Disease (HD) using a gene therapy has been given the clearance to go ahead in France.  The National Agency for Safety of Medicines and Health Products (ANSM) gave the go-ahead to Bayer AG to conduct the clinical trial through its subsidiary BrainVectis to investigate its […]

Collaboration to develop landmark novel antibody therapy for Huntington’s

17 March 2021

Alchemab, a biotech company harnessing the power of naturally protective antibodies, has been awarded a UK Biomedical Catalyst early award grant from Innovate UK to support its collaboration with Medicines Discovery Catapult and the development of a novel disease-modifying antibody therapy for Huntington’s disease. Using its novel approach, Alchemab has identified a panel of antibodies […]